European Antibody Congress - Agenda Day 1

 

European Antibody Congress 2018, Day 1

08:00 Registration Opens

08:30 Conference doors open

08:45

Welcome from Terrapinn

Opening Keynotes

Chaired by Alain Beck, Senior Director, NBEs Analytical Chemistry, Pierre Fabre, Associate Editor, mAbs

09:00

Protein therapeutics in big pharma

Peter Senter
09:20

The past, present, and future of antibody-drug conjugates

Dr Rakesh Dixit
09:40

Advancements in antibody drug conjugates: therapeutic challenges of safety and efficacy

  • Next generation ADCs with improved antibodies, payload, linkers, conjugation technology
  • Lessons learned from the clinical development of ADCs
  • Maximizing efficacy while minimizing toxicities
  • ADC disposition, PK-PD challenges
  • Translational challenges to ADC development
  • Looking at the future of ADCs
 
10:00

Title to be confirmed

Senior Executive, Fujifilm Diosynth Biotechnologies

10:20 Networking refreshment break

round tables
11:35

Plenary roundtable session

Table 1: Analytical and structural characterization of mAbs, biosimilars, ADCs, BsAbs, pAbs
Dr Alain Beck

Dr Alain Beck, Senior Director, Analytical Chemistry, NBEs, Centre d'Immunologie Pierre Fabre

Table 2: Indication selection/expansion and early biomarker discovery for bispecifics
Dr Jiri Kovarik

Dr Jiri Kovarik, Research Investigator, N.I.B.R.

Table 4: Muilti-specific formatomics – how much format diversity is required to address biology and developability?
Thomas Huber

Thomas Huber, Senior Investigator, Novartis Institute for Biomedical Research

Table 5: Clinical trials for antibodies
Table 6: Safety and efficacy for protein therapeutics
Table 7: Advances in multiplexing for clinical diagnosis
Lee Dawson

Lee Dawson, Senior Scientist, Molecular Pathology Group, Asterand Bioscience

Table 8: Reserved for supporting partner
Table 9: Reserved for supporting partner
12:25

Speed Networking

A fun, exciting and effective way to make a lot of initial connections (in a very different environment from the standard business networking meetings).

12:35 Networking Lunch

Engineering and structure

Bispecific development - Pre-clinical development

Armed antibody discovery

Regulations

Chaired by TBC

Chaired by TBC

Chaired by TBC

Chaired by TBC

Protein Engineering
14:10

Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye

  • Formulation and stability pose challenges for ocular biotherapeutics
  • Selection or re-engineering of protein therapeutics may be required for ocular delivery
  • Antibody Fab formulation and/or conjugation can be used to alter dosing frequency
 
Bispecifics
14:10

Immunoglobulin domain interface exchange as a platform technology to engineer bispecific antibodies

  • Bispecific antibodies based on heavy chain hetero-dimerization
  • Common light chain format
  • Clinical stage antibodies
 
Armed Antibodies
14:10

Antibody-tubulysin conjugates display activity in MDR+ and bystander activity models

  • Tubulysin M and stabilized analogues were compared as ADC payloads
  • Quaternary ammonium-linked tubulysin linkers were evaluated for activity in models of multidrug resistance and antigen-heterogeneity
  • Tubulysin linkers are a promising payload class, combining potency in MDR+ and antigen-heterogeneous tumor models in a structure-dependent manner
 
Regulation and Investment
14:10

Bioassays for therapeutic proteins: design, validation and beyond

  • Bioassays are an integral component of quality control testing in the development of therapeutic proteins, including monoclonal antibodies.
  • Assay acceptability depends on product type, mechanism of action, associated risk, phases of development, and availability of other quality data
  • This presentation provides regulatory expectations on bioassays with case studies highlighting the relevant issues commonly seen in the regulatory submissions
Protein Engineering
14:30

Structural and functional role of antibody variable domain glycosylation

  • What is the impact of variable domain glycans on structural aspects of IgG?
  • How do variable domain glycans shape the repertoire of antibody responses?
  • How is the functionality and immunobiology of IgG modulated by variable domain glycans?
 
Bispecifics
14:30

Analytical characterisation of BEAT bispecific antibodies

  • Glenmark’s BEAT technology features heterodimerisation of heavy chain by bio-mimicry
  • scFv x FAB format allows for versatile combinations without use of common light chain
  • BEAT molecules have unique features – beneficial for manufacturing process, and requiring appropriate application of analytical techniques
  • This presentation would provide an overview of analytical techniques used for BEAT molecules, compared to “classic” monoclonal antibodies
 
 
Armed Antibodies
14:30

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Bispecifics
14:50

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
 
Armed Antibodies
14:50

Development of potent and efficacious with payloads that target tubulin

  • Payload and linker development
  • In vitro screening
  • In vivo efficacy
 
Regulation and Investment
14:50

When the cake gets small: broad antibody claims in a crammed field

  • The breadth of allowable claims depends on the available prior art
  • A well characterized epitope may form the basis of a broad  claim
  • Broad antibody composition claims
  • Good fall back position needed in case of attack in Opposition proceedings
 
Protein Engineering
15:10

Reserved for Isogenica

 
Bispecifics
15:10

ATOR-1015 is a CTLA-4 x OX40 bispecific immune activating antibody developed for tumor-directed immunotherapy

  • ATOR-1015 binds both targets simultaneously, promoting cell-cell interactions expected to enhance the immuno-stimulating effects
  • The mode of action of ATOR-1015 is a combination of regulatory T cell (Treg) depletion and effector T cell activation
 
 
Regulation and Investment
15:10

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297

15:30 Networking refreshment break

Engineering and structure

Bispecific development - Clinical development

Armed antibody discovery

Investment

Chaired by TBC

Chaired by TBC

Chaired by TBC

Chaired by TBC

Protein Engineering
16:30

Efficient and safe antibody delivery across the blood brain barrier

  • The cerebrovascular network constitutes an efficient route for biologics to the brain
  • Engagement with the Blood Brain Barrier receptor crucial for efficient brain exposure
  • Antibodies with full effector function can be delivered in a stealth mode to the brain
 
Regulation and Investment
16:30

Turning ‘crazy’ ideas into experimental drugs

Protein Engineering
16:50

Reserved for Abzena

Bispecifics
16:50

Identifying and targeting escape mechanisms in AML using multispecific antibody derivatives

Armed Antibodies
16:50

Protein-polymer conjugation to increase residence time of a Fab therapeutic in the eye

  • Understanding the role that hydrodynamic size plays in clearance from the vitreous
  • Polymer-Fab conjugation as a strategy for extending size
  • Development of a accompanying biophysical toolbox
 
Whitney Shatz, Senior Scientific Researcher, Genentech
Regulation and Investment
16:50

Panel: Investors in biologics

  • What do investors look out for in start-ups?
  • What are the current trends for biologics?
  • Where do we see the industry moving to in the next 5-10 years?
  • How can you gain investment?
 
Protein Engineering
17:10

Antibody engineering to overcome antigen mediated clearance in vivo

  • Antibodies targeting membrane bound antigens with a high rate of synthesis are rapidly eliminated from plasma by antigen mediated clearance, thus compromising their therapeutic utility
  • We present a case study to describe a protein engineering approach to generate a pH dependent binding antibody directed to a receptor
  • The resulting antibody has an extended half-life in vivo and its efficacy is not limited by dose
 
Bispecifics
17:10

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Armed Antibodies
17:10

Differentiating DeBouganin’s MOA from small molecules as ADC payloads

  • The In vitro potency of deBouganin versus that of traditional small molecule drugs as payloads for tumour-targeted therapeutics (ADCs) will be discussed
  • Data will be presented demonstrating that deBouganin induces biomarkers associated with immunogenic cell death and does not enrich the presence of immunosuppressive cell surface markers
  • The presented studies will support the use of DeBouganin-loaded ADCs to both directly kill tumour cells and spark host immune responses that could pair well with the use of checkpoint inhibitors
 

CMC and Developability

Chaired by TBC

Protein Engineering
17:30

Physical stability – structural homogeneity of biotherapeutic antibodies: property prediction by in silico methods

  • Discovery and development of biotherapeutic mAbs is a multiparametric optimization to balance biological and pharmaceutical properties such as stability
  • Stability refers to intricate structural, chemical, and physical processes. Methods for theoretical prediction of these processes generally focus on particular aspects, not on the global outcome of such modifications
  • We will report on a knowledge-based approach to predict aspects of stability by combining homology modelling, structural descriptor calculations, and classification algorithms
Bispecifics
17:30

Bispecific DART® Molecules in the age of cancer immunotherapy: redirected T cell killing and beyond

  • Notwithstanding recent progress, unmet needs still exist in immunotherapy of cancer
  • Bispecific molecules may offer unique opportunities to address such needs
  • Application of the DART platform in redirected T‐cell killing, checkpoint blockade and co‐stimulation will be presented
 
Armed Antibodies
17:30

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
CMC and Developability
17:30

Modern analytical development of biologics

  • Feasibility of modern analytical tools for biologics development
  • Innovative approaches for process analytics
  • Trends and upcoming requirements for the analytical control of biopharmaceuticals

Targeting and specificity

Chaired by TBC

Protein Engineering
17:50

Mechanistic insight into transferrin receptor-mediated BBB shuttling antibodies based on VNARs

  • Novel approach for discovery of BBB penetrating antibodies
  • Optimisation of efficacy of BBB transporters
  • Mechanistic requirements for VNAR-based BBB shuttling antibodies
 
Bispecifics
17:50

BiTE® antibody constructs in clinic and development

  • Following the approval of blinatumomab in relapsed/refractory ALL multiple BiTE candidates have entered or are about to enter the clinic in various indications
  • Give an update on Amgen’s BiTE pipeline at the discovery, translational, and early clinical stage of development
 
Armed Antibodies
17:50

New Payloads for Antibody-Drug Conjugates

CMC and Developability
17:50

Reserved for Sartorius Stedim Biotech

Protein Engineering
18:10

Structure guided rational design of de novo antibody specificity

  • Engineered rat specificity de novo into Amgen’s lead anti-migraine molecule (AMG334
  • Fine tuning of specificity to gain Rat specificity without losing the human one
  • Structural computational approach, used in parallel with other engineering yielding the best results in terms of time vs effort vs cost
  • Investigated deep sequencing to enhance and de-risk the Ab engineering process
 
Bispecifics
18:10

Identification of a DP-L1 binding FCAB: A potent inhibitor of immunosuppressive signals

  • F-star has produced an Fcab, an antibody Fc domain modified to bind to a target, specific to PD-L1 The Fcab exhibits high affinity to human PD-L1 that translates into strong potency in cell-based functional assays
  • An anti-murine surrogate molecule, with similar potency, also exhibits activity in an MC38 syngeneic tumour model. This activity is improved when the Fcab is paired with Fabs targeting other immune checkpoint regulators
 
Armed Antibodies
18:10

DARPin-photosensitizer conjugates for EpCAM-directed photodynamic therapy of ovarian cancer

  • Designed ankyrin repeat proteins
  • Photodynamic therapy
  • Ovarian cancer
  • Epithelial cell adhesion molecule (EpCAM)
 
CMC and Developability
18:10

Developability assessment of therapeutic proteins – a toolbox for tackling increasing complexity

  • The concept of developability assessment of therapeutic proteins
  • Analytical challenges upon the shifting of biologics portfolio
  • Strategies and tool-box addressing the new demand 
  • Case studies highlighting the analytical method development
 

18:30 Offsite networking drinks

last published: 13/Jul/18 08:35 GMT

 

Mark Your Calendars Now!
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates